For the third consecutive year, Aferetica is among Growth Leaders (https://lab24.ilsole24ore.com/leader-della-crescita-2023/). The ranking by Sole 24 Ore and Statista brings together the 450 Italian SMEs capable of competing at European level. Statista, according to their average annual growth rate over the three years (Cagr).
This important acknowledgment comes at the end of an intense year, in which more than 50 transplants were carried out in Bari, Bergamo, Milan, Padua, Pisa, Verona, Barcelona, Berlin and Groningen thanks to the PerLife® system and its integration with PerSorb®, developed in collaboration with the US company CytoSorbents.
In addition, on the occasion of the last Workshop Purification Therapies ‘From Research to Clinical Evidence’, more than 450 experts from the international scientific community gathered to discuss crucial issues, not only in transplantation, but also in the application of extracorporeal therapies in inflammatory syndromes.
The rapid and progressive expansion into the European markets also saw Aferetica enter Spain, the first country in terms of number of transplants by population in the world, Holland, where it collaborates with the University of Groningen, and Germany, with the admission to the Charitè Hospital in Berlin.
The partnership network for innovation developed by Aferetica sees collaborations with research structures in the Emilia-Romagna area, including Mario Veronesi Technopole, University of Bologna, University of Ferrara, and with the entrepreneurial fabric of the area, including companies such as Dinamica Generale of Poggio Rusco and SIDAM of Mirandola.
Aferetica closed 2021 with a constant growth rate (CAGR 64%). There are currently 20 employees, including 10 women, with and over 100 human resources involved in the production of apheresis therapeutic systems.
A new achievement that shows daily commitment and dedication, always pursuing the mission of developing comprehensive and integrated apheretic therapies dedicated to the life and well-being of the patient.
